title: Rivaroxaban inhibits oxidative and inflammatory reactions in advanced glycation end product-exposed tubular cells by blocking thrombin/protease-activated receptor-2 system.
authors: Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume, Japan.
authors: Yuji
authors: Y
authors: Ishibashi
authors: Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume, Japan.
authors: Takanori
authors: T
authors: Matsui
authors: Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
authors: Kei
authors: K
authors: Fukami
authors: Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
authors: Seiji
authors: S
authors: Ueda
authors: Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
authors: Seiya
authors: S
authors: Okuda
authors: Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume, Japan. Electronic address: shoichi@med.kurume-u.ac.jp.
authors: Sho-ichi
authors: S
authors: Yamagishi
mesh_terms: D065427:Factor Xa Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D006801:Humans; D007249:Inflammation / Q000378:metabolism*; D018384:Oxidative Stress; D044464:Receptor, PAR-2 / Q000378:metabolism*; D000069552:Rivaroxaban / Q000008:administration & dosage / Q000627:therapeutic use*; D013917:Thrombin / Q000378:metabolism*
chemical_list: D065427:Factor Xa Inhibitors; D017127:Glycation End Products, Advanced; D044464:Receptor, PAR-2; D000069552:Rivaroxaban; D013917:Thrombin